Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — H1 2022 Earnings Presentation
16 slides from Innate Pharma Sa Class A's earnings presentation, Sep 15, 2022
Slide 1: Half Year 2022 Financial Results and Business Update
Half Year 2022 Financial Results and Business Update September 15, 2022 PARIS: IPH.PA NASDAQ: IPHA © 2021 Innate Pharma. All rights reserved.
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 3: Speakers on Today's Call
Speakers on Today’s Call Mondher Mahjoubi, MD Joyson Karakunnel, MD, MSc, FACP Chief Executive Officer EVP, Chief Medical Officer Chairman of the Executive Board Yannis Morel, PhD Frédéric Lombard, MBA EVP, Business Development and SVP, Chief Financial Officer Product Portfolio Strategy 3
Slide 4: Early R&D Focus to Drive Value Through Later Stage Partnerships
Early R&D Focus to Drive Value Through Later Stage Partnerships Drive near-term Advance our Build sustainable value with innovative R&D business through Lacutamab pipeline partnerships • Announced data-driven clinical • IPH6401 ANKETTM BCMA • PACIFIC-9 Phase 3 NSCLC start development plan for PTCL s
Slide 5: Our Robust Pipeline of Proprietary & Partnered Assets
Our Robust Pipeline of Proprietary & Partnered Assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Comments Sézary Syndrome TELLOMAK (FDA FAST TRACK/EMA PRIME DESIGNATION) Preliminary Phase 2 data expected H2 2022 Early data presented Mycosis Fungoides TELLOMAK Preliminary Phase 2
Slide 6: TELLOMAK Phase 2 Study in Two CTCL Subtypes
LACUTAMAB TELLOMAK Phase 2 Study in Two CTCL Subtypes Potential for Sézary syndrome cohort to serve as pivotal trial Sézary Syndrome (N~60) Mycosis Fungoides (N~100) ≥ 2 prior systemic therapies ≥ 2 prior systemic therapies Cohort 1 Cohort 2# Cohort 3# All Comers* All comers, SS, must include KIR3DL
Slide 7: Developing a New Standard of Care Across KIR3DL2 Expressing T-Cell Lymphomas
LACUTAMAB Developing a New Standard of Care Across KIR3DL2 Expressing T-Cell Lymphomas Cutaneous T-Cell Lymphoma (CTCL) Peripheral T-Cell Lymphoma (PTCL) Phase 2 TELLOMAK Trial Multi-trial Strategy Sezary Syndome Mycosis Fungoides From Relapsed to Frontline PTCL 80-200 patients 2,200-4,400 patients
Slide 8: Monalizumab: a strong potential in association in the NSCLC
MONALIZUMAB Monalizumab : a strong potential in association in the NSCLC Dual mechanism of action with AstraZeneca’s durvalumab NK Cell Monalizumab blocks the NKG2A receptor on both NK cells and cytotoxic CD8+ T cells Cancer cell The two antibodies act synergistically to block the inhibitory action
Slide 9: Monalizumab: Early NSCLC
MONALIZUMAB Monalizumab: Early NSCLC Phase 3 program underway, sponsored by AstraZeneca, for patients with unresectable, Stage III NSCLC NSCLC Phase 3 in unresectable, Stage III NSCLC STAGE I STAGE II STAGE III STAGE IV Phase 2 NeoCOAST* Phase 2 COAST* Stg I-IIIA NSCLC Unresect. Stg III NSCLC monali
Slide 10: Adenosine Pathway: IPH5301 and IPH5201
ADENOSINE Adenosine Pathway: IPH5301 and IPH5201 Clinical trials underway IPH5201* (anti CD39): Phase 1 clinical trial design Combination Monotherapy IPH5201 IPH5201 + durvalumab PART 1 PART 2 Phase 2 planning underway in NSCLC IPH5301 (anti CD73): Design of the Phase 1 clinical trial ISS CHANCES Tu
Slide 11: ANKET: Innate's Proprietary NK Cell Engager Platform
ANKETTM ANKET™: Innate’s Proprietary NK Cell Engager Platform ANKET™ Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46 is a versatile, fit-for- purpose technology that is creating Provides proliferation and activation signals
Slide 12: Two molecules from Innate ANKET engine selected by Sanofi
ANKETTM Two molecules from Innate ANKETTM engine selected by Sanofi Anti-CD123 IPH6101/SAR’579 currently in Phase 1 in AML ; Anti-BCMA IPH6401/SAR’514 progressing toward IND Multispecific antibody engineering targeting a tumor antigen, NKp46 and CD16a IPH6101/SAR’579 IPH6401/SAR’514 €13M milestone p
Slide 13: First Half of 2022 Financial Highlights
First Half of 2022 Financial Highlights Cash, cash equivalents and financial assets: €158.2m* as of June 30, 2022 • Sufficient to fund operations into H2 2024 Revenue/other income from Operating expenses from continuing operations: continuing operations: €45.6m €37.1m Licensing and collaborations: €
Slide 14: Key Newsflow Over the Next 18 Months
Key Newsflow Over the Next 18 Months H 2 2 0 2 2 Data Readouts Clinical Progress • Lacutamab Phase 2 MF data (preliminary) (EORTC) • IPH5201 (CD39) Phase 2 start (AstraZeneca partnership) • Lacutamab Phase 2 SS data (preliminary) • IPH5301 (CD73) Phase 1 start (IST) • IPH5201 (CD39) Phase 1 data (As
Slide 15: Early R&D Focus to Drive Value Through Later Stage Partnerships
Early R&D Focus to Drive Value Through Later Stage Partnerships Lacutamab R&D pipeline Partnerships • TELLOMAK read-out with MF in • Advancing proprietary tetra- • Phase 3 monalizumab 2021 and preliminary data for MF specific NK cell-targeted platform collaboration with AstraZeneca and SS in 2022 an
Slide 16: Questions and Answers
Questions and Answers &S innate pharma